Factors associated with physician perceptions of and willingness to recommend inhaled insulin

Current Medical Research and Opinion

Volumn 27, Issue 2, 2011, Pages 285-294

  Rubin, R R ^a   Peyrot, M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

Author keywords

Inhaled insulin; Physician perceptions; Prescription practices; Survey

Indexed keywords

INSULIN; RECOMBINANT HUMAN INSULIN;

ARTICLE; DECISION MAKING; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; GENERAL PRACTITIONER; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MEAL; PERCEPTION; PHYSICIAN; PRESCRIPTION; UNITED STATES;

ADMINISTRATION, INHALATION; ADULT; ATTITUDE TO HEALTH; CAUSALITY; CHOICE BEHAVIOR; DATA COLLECTION; DIABETES MELLITUS; HUMANS; INSULIN; PATIENTS; PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; QUESTIONNAIRES;

EID: 78651383519     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.541434     Document Type: Article

References (22)

1. Editorial. Patient choice stops at inhaled insulin. Lancet 2006;367:1372
2. Del Prato S, Blonde L, Martinez L, et al.;on behalf of the EXPERIENCE Trial Team. The effect of the availability of inhaled insulin on glycaemic control in patients with type 2 diabetes failing on oral therapy: the evaluation of Exubera®as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. Diab Med 2008;25:662-70
3. Quattrin TA, Belanger A, Bohannon JHV, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622-7
4. Skyler JS, Weinstock RS, Raskin P, et al.;Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:163-5
5. Skyler JS, Jovanovic L, Klioze S, et al.;Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-85
6. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-62
7. Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-7
8. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-58
9. Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and gly-cemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23
10. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
11. Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol 2008, 3, 518-29.
12. Rosenstock J, Bergenstal R, DeFronzo RA, et al.;for the 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-näve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31:2177-82
13. Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther 2010;12:49-55
14. Segal R, Helper CD. Drug choice as a problem-solving process. Med Care 1985;23:967-76
15. Schumock GT, Walton SM, Paark HY, et al. Factors that influence prescribing decisions. Ann Pharmacother 2004;38:557-62
16. Peyrot M, Rubin RR. Physician perception, recommendation and use of insulin pens for patients with type 2 diabetes. Curr Med Res Opin 2008;24:2413-22
17. Grant RW, Wexlr DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic gener-alists. Diabetes Care 2007;30:1448-53
18. Peyrot M, Rubin RR, Lauritzen T, et al.;on behalf of the International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care 2005;28:2673-9
19. Rosenstock J, Lorber DL, Gnuidi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomized trial. Lancet 2010;375:2244-53
20. TM or usual antidiabetic treatment. Diabetes 2009;58(Suppl 1):A153 (Abstract # 570)
21. Peyrot M, Rubin RR. How does treatment satisfaction work? Modeling determinants of treatment satisfaction and preference. Diabetes Care 2009;32:1411-17
22. Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive framework. Diabetes 2010;59 (sup 1)